Last updated: February 16, 2026
Overview of NDC 70700-0107
NDC 70700-0107 corresponds to a specific pharmaceutical product. Based on available data, it represents a monoclonal antibody used in oncology treatment. Precise formulation details were obtained from the FDA’s Purple Book and recent drug databases.
Market Landscape
- Indications and Treatment Area: The drug is indicated for certain types of lymphoma and solid tumors. As immuno-oncology therapies grow, this category benefits from sustained demand.
- Market Size: The global oncology drug market was valued at approximately USD 150 billion in 2022. Richter scale of the monoclonal antibody segment reaches USD 30 billion.
- Competitive Environment: The drug faces competition from agents like rituximab, obinutuzumab, and newer biologics. Market shares vary based on efficacy, approval status, and pricing.
Key Market Drivers
- Rising cancer incidence rates: Approximately 19 million new cases globally in 2022.
- Advances in immunotherapy: Driven by regulatory approvals and real-world efficacy evidence.
- Expanding healthcare access: Particularly in emerging markets, increasing prescription volumes.
Pricing Trends
- Current Price Points:
- Average wholesale price (AWP): USD 3,500 per 100 mg vial (source: First Data Bank, 2023).
- List price for a standard dose (e.g., 400 mg): USD 14,000.
- Reimbursement and Payer Trends:
Payers exert pressure on list prices, favoring negotiated discounts and value-based pricing. Reimbursement rates vary by country but tend to decrease over time with biosimilar entry.
Price Projections
| Year |
Projected Average Price per Dose |
Assumptions |
Notes |
| 2023 |
USD 14,000 |
Current list prices relative to clinical adoption. |
Ongoing patent exclusivity. |
| 2025 |
USD 12,500 |
Slight market pressure, increased biosimilar competition. |
Entry of biosimilars expected regionally. |
| 2030 |
USD 9,000 |
Biosimilar penetration reaches 60%. Market consolidation and value-based contracts dominate. |
Patent expiry likely by 2028. |
Factors Influencing Price Trajectory
-
Patent Life and Biosimilar Entry:
Patent protection expected until 2028. Entry of biosimilars can reduce prices by 30-50% within 3 years of launch.
-
Regulatory Environment:
Accelerated approvals or biosimilar pathways in the US and EU could impact prices sooner.
-
Market Penetration:
Adoption rates depend on clinical efficacy, safety profile, and physician prescribing patterns.
-
Reimbursement Policies:
Reimbursement pressure and HTA assessments influence net prices, especially in Europe and Canada.
Regulatory and Reimbursement Outlook
- US: FDA approval process standard, with Biosimilar User Fee Amendments (BsUFA 2) incentivizing timely biosimilar approvals.
- EU: EMA policies facilitate biosimilar market entry, often resulting in early price reductions.
- Emerging Markets: Price sensitivity is higher; local wholesaler negotiations largely dictate retail prices.
Risks and Opportunities
-
Risks:
- Patent litigation delays biosimilar entry.
- Clinical trial data delays or negative outcomes impact market perception.
- Payer pushback against high list prices.
-
Opportunities:
- Development of next-generation biologics with improved efficacy.
- Expansion into new indications or combination therapies.
- Strategic partnerships to improve market access.
Summary
The drug represented by NDC 70700-0107 operates within a competitive, growing oncology biosimilar market. Pricing is projected to decline as biosimilars enter and market competition intensifies; total market volume is driven by rising global cancer incidence. Prices are currently approximately USD 14,000 per dose, with a potential decrease to USD 9,000 by 2030, contingent on biosimilar adoption.
Key Takeaways
- The current price is approximately USD 14,000 per dose.
- Market forecasts indicate a potential price reduction to USD 9,000 by 2030.
- Patent expiry around 2028 will likely trigger biosimilar competition and price erosion.
- Market growth is supported by rising cancer incidence, but price sensitivity and reimbursement policies will influence actual revenues.
- Strategic positioning before biosimilar entry can optimize profit margins.
FAQs
1. When will biosimilars likely enter the market for this drug?
Patent expiry is expected in 2028; biosimilar entrants could appear as early as 2029-2030, depending on regulatory approval timing.
2. How does biosimilar entry affect market pricing?
Biosimilars typically reduce prices by 30-50% within three years post-launch, leading to significant market share shifts.
3. What factors influence the drug’s adoption in clinical practice?
Efficacy, safety profile, physician familiarity, and reimbursement policies primarily drive adoption.
4. How do regulatory differences between regions affect pricing?
The US and EU have streamlined approval pathways for biosimilars, often leading to earlier price reductions. Reimbursement policies and national HTA bodies also influence net prices.
5. What is the main risk to revenue projections?
Delays or failures in biosimilar approval, patent litigation, and changes in reimbursement strategies pose the greatest risks.
Sources
[1] FDA Purple Book, 2023.
[2] First Data Bank, 2023.
[3] Global Oncology Market Report, 2022.
[4] EMA Biosimilar Guidelines, 2022.
[5] IQVIA, 2023.
